Topic: hormone replacement therapy
Even as major drug pricing scandals such as EpiPen gained national attention, routine price hikes on another drug largely went unnoticed.
AbbVie is in court facing the first of 4,100 defendants in a class action alleging its testosterone drug AndroGel caused cardiovascular problems.
AMAG Pharmaceuticals has big ambitions for its women’s health business, so it’s snapped up the rights to a new med, Intrarosa, to beef up that portfolio. And it’s bringing on 150 new reps to detail the med.
Manufacturing problems have led to the recall of the thyroid-hormone replacement therapy Synthroidfor the second time in 6 months.